Shots:
The EMA’s CHMP has granted approvals to 1 Biologic and 3 new chemical entities in August 2025, leading to treatments for patients and advances in the healthcare industry Â
The major highlighted drug was Gilead’s Yeytuo has Secured the EC’s Approval for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV  Â
PharmaShots has compiled a list of 4…
Shots:
The EMA’s CHMP has granted positive opinions and approvals to 3 Biologics and 10 new chemical entities in July 2025, leading to treatments for patients and advances in the healthcare industry Â
The major highlighted drug was Roche’s Itovebi Secures the EC’s Approval for PIK3CA-mutated Breast Cancer  Â
PharmaShots has compiled a list of 13 drugs…
Shots:
In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCLÂ
Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progressionÂ
PharmaShots welcomes Dr. Ira Zackon,…
Shots:
Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancerÂ
While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
Shots:
In an insightful interview with PharmaShots, Sujay Jadhav, CEO of Verana Health, discusses VeraSite, a recently launched subscription-based tool for clinical trial site selection Â
To gather real-world data, Verana Health leverages the VeraQ population health data engine and transforms the structured and unstructured data into curated disease-specific modules called QData Â
Currently available in the…

